Industry-Sponsored Satellite Symposia
Open to all ACG 2023 attendees, industry-sponsored satellite symposia provide additional educational opportunities for attendees. These programs are independent of the ACG 2023 Annual Scientific Meeting & Postgraduate Course programs. ACG is not the continuing medical education provider of these programs. For more information, see the company sponsor.
Friday, October 20
Mastering the Management of IBD: Challenging Cases
TBD
6:00 pm – 7:30 pm • Fairmont Waterfront Hotel, Waterfront Ballroom AB
The treatment landscape for inflammatory bowel disease (IBD) is evolving rapidly, as novel pharmacologic agents continue to advance the treatment of Crohn’s disease and ulcerative colitis. In this live symposium, 3 IBD experts will discuss and differentiate these new and emerging therapies, provide context for their use in clinical practice, and use patient cases to illustrate evolving concepts in risk stratification, treat-to-target approaches, and therapeutic monitoring. The symposium will be presented in a “Test and Teach” format that will pose challenging, case-based questions to the audience to explore the learner’s current knowledge and therapeutic approach, and then “teach” through them in-depth, evidence-based discussion. The program will conclude with an interactive audience Q&A session.
This activity is supported by an independent educational grant from AbbVie Inc.
Saturday, October 21
An Overview of Health Disparities in IBD
Marla C. Dubinsky, MD; Damie Odufalu, MD
5:30 pm – 7:30 pm • Fairmont Waterfront Hotel, Waterfront Ballroom
This symposium will review the definition of health disparities, provide an overview of health disparities in IBD, and present possible strategies that could help reduce barriers to health equity.
This program is sponsored by Pfizer.
Eosinophilic Esophagitis: Optimizing Diagnosis and Treatment for Improved Patient Outcomes – A Wheel of Knowledge Challenge!
Evan S. Dellon, MD, MPH, FACG; Nirmala Gonsalves, MD, FACG; Joy W. Chang, MD, MS; Calies Menard-Katcher, MD, MSCs
5:30 pm – 7:30 pm • Vancouver Convention Centre, East Ballroom A
Don’t miss this hybrid CME/CNE/AAPA-certified symposium where expert faculty will review the pathogenesis and risk factors for EoE, the modalities and best practices for accurate diagnosis of EoE, and the most recent guidelines and clinical data that aid in the selection of optimal treatment regimens. BONUS: This program includes A Wheel of Knowledge Challenge, a highly interactive gaming segment in which your team will partner with a faculty member to compete against your peers!
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc., and Sanofi.
Expert Guidance on Harnessing New Therapeutic Approaches in Ulcerative Colitis
TBD
7:30 pm – 9:30 pm • Vancouver Convention Centre, East Ballroom B
Join us for a CME/CE-certified program that provides expert guidance on the role of S1P receptor modulation, the implications of JAK inhibitor selectivity, and the positioning of new and approved therapies in UC treatment plans.
This program is supported by an educational grant from Pfizer, Inc.
Practical Management of Variceal Bleeding and Hepatorenal Syndrome: Evidence-Based Interventions in Complications of Cirrhosis
Chair: Andrew P. Keaveny, MD
Faculty: Michael P. Curry, MD; Don C. Rockey, MD, FACG
7:30 pm – 9:30 pm • Pinnacle Hotel, Harborfront Ballroom
This educational program is designed to equip gastroenterologists with an in-depth understanding of two critical aspects of advanced liver disease: variceal bleeding and hepatorenal syndrome. These complications pose significant challenges in the management of patients with cirrhosis.
This activity is supported by an educational grant from Mallinckrodt Pharmaceuticals.
Sunday, October 22
Treatment Selection in Ulcerative Colitis: Optimizing Outcomes through Patient-Centered Decision Making
Marla C. Dubinsky, MD; Bruce E. Sands, MD, MS, FACG
5:30 am – 7:30 am • Vancouver Convention Center West, Room 301
This interactive educational program is designed to provide gastrointestinal healthcare providers with patient-centered strategies to individualize therapy selection in ulcerative colitis. Using a combination of didactic lecture and animated/video simulation case challenges, this program aims to increase clinician knowledge of the safety, efficacy, and mechanism of action of recently approved and emerging therapies; and improve their ability to incorporate the assessment of bowel urgency into management strategies for patients with ulcerative colitis.
This activity is supported by an educational grant from Lilly.
Crohn’s Disease Management: The Power of “What Else?
Remo Panaccione, MD, FRCPC
7:30 pm – 9:30 pm • Pinnacle Hotel, Harborfront Ballroom
Join our experts as they discuss strategies to empower healthcare providers and their patients with Crohn’s disease to move from settling for less to asking for more. Dinner will be served from 7:30 pm.
This program is sponsored by Eli Lilly and Company
Building Bridges, Closing Gaps in NASH Care: The Pivotal Role of Gastroenterologists
Kimberly A. Brown, MD; Mazen Noureddin, MD; Alina M. Allen, MD
7:30 pm – 9:30 pm • Fairmont Waterfront Hotel, Waterfront Ballroom C
This interactive symposium aims to position gastroenterologists to improve patient care and outcomes by increasing their awareness of NAFLD/NASH and enhancing their ability to engage patients with NAFLD in the clinical care pathway. Expert faculty will take a deep dive into late-stage clinical trials to address unmet clinical needs and the potential for new agents to address them. Gastroenterologists will benefit from reviewing the safety and efficacy data, as it will help prepare them to quickly integrate new agents into their practice when these agents become available.
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Monday, October 23
Managing Recurrent Clostridioides Difficile Infection: Advancing the Science of Microbiome-Based Therapies
Paul Feuerstadt, MD, FACG; Teena Chopra, MD, MPH; Anne J. Gonzales-Luna, PharmD, BCIDP
5:30 am – 7:30 am • Vancouver Convention Centre East, East Ballroom A
Join a panel of two expert clinicians as they discuss new and emerging microbiome-based therapies for preventing recurrent Clostridioides difficile infection and how these agents may substantially improve patient quality of life. Earn 1.5 AMA PRA Category 1 CreditTM or 1.5 Accreditation Council for Pharmacy Education (ACPE) contact hour. Complimentary breakfast provided! Visit the Gastroenterology & Endoscopy News exhibit booth, #1714, for more information.
This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc.
Exclusive from Vancouver: A Spotlight on Ulcerative Colitis Experts
David T. Rubin, MD, FACG; Bruce E. Sands, MD, MS, FACG; Marla C. Dubinsky, MD
7:00 pm – 8:30 pm • Pinnacle Hotel, Cordova Ballroom
Join us for the unique opportunity to engage with experts as they share their personal insights on ulcerative colitis management. Dinner will be served from 7:00 pm.
This program is sponsored by Eli Lilly and Company
A New Era in the Management of Gastroesophageal Reflux Disease
TBD
7:30 pm – 8:45 pm • Fairmont Waterfront Hotel, Waterfront Ballroom C
Gastroesophageal reflux disease (GERD) is a highly prevalent, chronic gastrointestinal disorder that can result in serious complications if undertreated. Proton pump inhibitors (PPIs), the mainstay of GERD treatment, are generally safe and effective; however, some patients undergo PPI therapy for years but have recurrent or refractory symptoms. A new class of acid-suppressing therapies is in late-stage clinical development and nearing approval. In this live, interactive townhall, expert faculty will discuss the latest evidence regarding the diagnosis and management of GERD and erosive esophagitis (EE), including new medical therapies. Faculty will use patient cases to contextualize clinical information on GERD diagnosis and management that learners can apply in their own practices.
Supported by an independent educational grant from Phathom Pharmaceuticals.